Scarica l'app Stockscreener
0.423
5.79%
-0.026
Dopo l'orario di chiusura:
.44
0.017
+4.02%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SCLX Giù?
Forum
Previsione
Scilex Holding Company Borsa (SCLX) Ultime notizie
Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1) - The Manila Times
Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025 - The Manila Times
Scilex seeks FDA nod for ELYXYB in acute pain management - MSN
Scilex Holding Company Announces that It Will Be Filing Today of a Supplemental New Drug Application with the FDA for ELYXYB® in Acute Pain Indication - The Manila Times
Scilex Holding Company Announces Filing of its Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2024 - The Manila Times
Scilex Holding Company Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Scilex Holding Company (SCLX) reports earnings - Quartz
Jane Street Group LLC Trims Position in Scilex Holding (NASDAQ:SCLX) - Defense World
Scilex Holding Company Amends its License Agreement with Romeg Therapeutics, LLC, For the Worldwide Rights to Commercialize Gloperba®, an FDA-Approved Prophylactic Treatment for Painful Gout Flares in Adults - Yahoo Finance
Manulife Mltfactor US Mid Cap Hgd ETF (MUMC-T) QuotePress Release - The Globe and Mail
Scilex Holding Company Announces Pain Medicine News Published Retrospective Claims Data on ZTlido® vs. Lidocaine 5% Patch - The Manila Times
Scilex (NASDAQ:SCLXW) Trading Up 22.5% – Here’s Why - Defense World
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination - The Manila Times
Thinking about buying stock in Scilex Holding, iCoreConnect, Genius Group, Helius Medical Technologies, or TradeUP Acquisition? - Marketscreener.com
**Scilex Holding Co Changes Record Date for Dividend Payment**** - Defense World
Scilex Adjusts Record Date for Preferred Stock Dividend - TipRanks
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from November 7, - The Manila Times
Scilex Holding Shifts Semnur Pharmaceuticals Dividend Record Date to January 2025, Updates Preferred Stock Distribution - StockTitan
Scilex Holding (NASDAQ:SCLX) Short Interest Down 14.0% in December - Defense World
Scilex Holding (NASDAQ:SCLX) Sees Large Decline in Short Interest - MarketBeat
State Street Corp Buys 54,404 Shares of Scilex Holding (NASDAQ:SCLX) - Defense World
Scilex (NASDAQ:SCLXW) Shares Up 4.7% – What’s Next? - Defense World
Scilex CEO Jaisim Shah buys $13,800 in company stock By Investing.com - Investing.com South Africa
Scilex CEO Jaisim Shah buys $13,800 in company stock - Investing.com India
Jaisim Shah Purchases 30,000 Shares of Scilex Holding (NASDAQ:SCLX) Stock - MarketBeat
SCLX stock touches 52-week low at $0.46 amid market challenges - Investing.com
Scilex Holding Co options imply 15.0% move in share price post-earnings - TipRanks
Palo Alto pharmaceutical company secures $17M - The Business Journals
Scilex Holding Company Announces Early Installment Payment on its Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation - The Manila Times
Scilex Holding Company Announces Early Installment Payment - GlobeNewswire
Scilex Holding Company closes registered direct offering - Medical Buyer
Holding Company Shares Rally Following Board Of Directors Commentary - MSN
Scilex Holding Company Announces Closing of $17 Million Registered Direct Offering - The Manila Times
Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt - The Eastern Progress Online
Scilex completes $17 million direct stock and warrant offering - Investing.com
Scilex Holding Co options imply 17.2% move in share price post-earnings - TipRanks
Scilex secures $17 million in stock and warrant sale - Investing.com
Scilex Holding Company Announces $17 Million Registered Direct Offering - The Manila Times
Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer's Disease (AD) Currently Enrolling with U.S. Patient Cohort to be Added in 2025 - The Manila Times
Scilex Bio says KDS201 currently enrolling with U.S. patient cohort to be added - TipRanks
Scilex Bio, a Controlling Interest of Joint Venture by - GlobeNewswire
Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer’s Disease (AD) Currently Enrolling with U.S. Patient Cohort to be Added in 2025 - Yahoo Finance
Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports Phase 2 Trial for Obesity Currently Enrolling with U.S. Patient Cohort to be Added in 2025. Scilex Bio Reports Positive Results from the Recently Completed Phase 1 Trials C - The Manila Times
NeuroBiogen Company and Scilex Bio Enter into Binding Term Sheet for Worldwide License, Along with the Rights to Sublicense for All of KDS2010 - Marketscreener.com
SCLX: Deal Brings Huge Potential - Research Tree
Scilex Holding agrees to share sale to meet debt obligations By Investing.com - Investing.com Nigeria
Scilex Holding agrees to share sale to meet debt obligations - Investing.com
Scilex Announces Joint Venture for CNS Compound Development - TipRanks
NeuroBiogen Company and Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company enter into Binding Term Sheet for Worldwide License, Along with the Rights to Sublicense for All of KDS2010 indications; Binding Term Sheet Includes C - The Manila Times
NeuroBiogen Company and Scilex Bio, a Controlling Interest - GlobeNewswire
1.22%
1.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):